Myovant Sciences Ltd

NYSE:MYOV   2:26:33 PM EDT
+1.30 (+6.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.93B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$59.09 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$20.58
50-Day MA$22.28
200-Day MA$21.73
See more pivots

Myovant Sciences Ltd Stock, NYSE:MYOV

11-12 St. Jamesâ??s Square, Suite 1, 3rd Floor, London, Greater London SW1Y 4LB
Phone: +44.207.400.3351
Number of Employees: 407


Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.